Vicor's PD2i nonlinear algorithm selected for CRY cardiac screening initiative

David H. Fater, CEO of Vicor Technologies, Inc. (OTCBB: VCRT), today announced that its PD2i® nonlinear algorithm has been selected by Dr. Sanjay Sharma to be used in a month-long cardiac screening initiative to be held in South East London in April 2010. Vicor Technologies is a biotechnology company focused on the commercialization of innovative, non-invasive medical devices and diagnostics using its patented, proprietary PD2i® nonlinear algorithm and software to stratify patients at risk of sudden cardiac death or autonomic dysfunction, and trauma victims in need of lifesaving intervention.

Dr. Sharma, consultant cardiologist of Cardiac Risk in the Young (CRY), is spearheading the screening initiative which will offer free cardiac screening to 14 year olds (DOB 1995) living in South East London; 14 is the earliest post-puberty age for which proactive screening is considered viable. Ten percent of the estimated seven million individuals fitting this description are expected to participate. Vicor's PD2i® nonlinear algorithm will be used along with ECG and echocardiogram to identify participants at risk of sudden cardiac death.

"The ultimate goal of this initiative is to develop a prototype for a national screening program for young sudden cardiac death, which is an extremely worthy goal, given that some 600 young people are struck down by sudden cardiac death annually in the U.K. We're honored to have our PD2i® nonlinear algorithm selected for use in this important initiative," stated Dr. Daniel Weiss, cardiologist and Vicor's Chief Medical Officer.

"Given the consistently accurate results achieved with the PD2i® nonlinear algorithm in risk stratifying adults at risk of sudden cardiac death, we're confident that the PD2i® nonlinear algorithm will prove beneficial in identifying 14 year olds participating in the initiative, who will then be able to obtain effective treatment," stated Mr. Fater.

SOURCE: Vicor Technologies, Inc.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Researchers discover novel candidate drug targets for advanced non-alcoholic fatty liver disease